Kymera Therapeutics, Inc. (KYMR) Shareholders & Insider Trades
Kymera Therapeutics shareholders at a glance
The largest holder of Kymera Therapeutics stock is Fidelity Management & Research Co. LLC, with 12.3 million shares (15.01% of the company), worth about $1.47 billion as of September 25, 2026. The 10 largest holders together own 73.6%.
In Q2 2026, 294 institutional holdings reports listed shares worth $11.10 billion.
Insiders reported 41 transactions in the last two years: 18 sales worth $15.04 million and 2 purchases. The newest one on file is from October 29, 2025 (Mainolfi Nello, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through October 29, 2025.
Kymera Therapeutics, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Kymera Therapeutics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Fidelity Management & Research Co. LLC | 12.3 million | 15.01% | $1.5B |
| Baker Bros. Advisors LP | 8.7 million | 10.52% | $1.0B |
| Avoro Capital Advisor LLC | 7.5 million | 9.09% | $888.0M |
| T. Rowe Price International Ltd. | 7.1 million | 8.65% | $845.0M |
| T. Rowe Price Investment Management, Inc. | 6.3 million | 7.61% | $743.0M |
| BlackRock Advisors LLC | 5.2 million | 6.33% | $618.0M |
| BVF, Inc. | 3.9 million | 4.71% | $460.0M |
| Wellington Trust Co., NA | 3.7 million | 4.47% | $437.0M |
| Vanguard Portfolio Management LLC | 3.0 million | 3.64% | $356.0M |
| The Invus Group LLC | 2.9 million | 3.57% | $349.0M |
As of September 25, 2026.
Kymera Therapeutics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 294 | – | $11.1B |
| Q1 2026 | 265 | – | $8.0B |
| Q4 2025 | 270 | – | $7.0B |
| Q3 2025 | 220 | 81.1 million | $4.6B |
| Q2 2025 | 222 | 79.0 million | $3.5B |
| Q1 2025 | 188 | 72.9 million | $2.0B |
| Q4 2024 | 190 | 71.7 million | $2.9B |
| Q3 2024 | 185 | 69.2 million | $3.3B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Kymera Therapeutics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Mainolfi Nello | Oct 29, 2025 | Chief Executive Officer | Sale at price 59.72 - 61.46 per share. | $1.8M |
| Mainolfi Nello | Oct 29, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 2.08 per share. | $62,400 |
| Gollob Jared August | Oct 15, 2025 | Officer | Sale at price 60.37 - 63.09 per share. | $3.7M |
| Gollob Jared August | Oct 15, 2025 | Officer | Conversion of Exercise of derivative security at price 1.31 - 2.08 per share. | $84,185 |
| Albers Jeffrey W | Oct 13, 2025 | Director | Sale at price 59.19 per share. | $295,949 |
| Gollob Jared August | Oct 13, 2025 | Officer | Sale at price 60.00 per share. | $186,840 |
| Albers Jeffrey W | Oct 13, 2025 | Director | Conversion of Exercise of derivative security at price 10.34 per share. | $51,700 |
| Gollob Jared August | Oct 13, 2025 | Officer | Conversion of Exercise of derivative security at price 1.31 - 2.08 per share. | $2,448 |
| Jacobs Bruce N. | Sep 17, 2025 | Chief Financial Officer | Sale at price 50.00 per share. | $4.0M |
| Jacobs Bruce N. | Sep 17, 2025 | Chief Financial Officer | Conversion of Exercise of derivative security at price 2.08 per share. | $164,778 |
| Mainolfi Nello | Sep 16, 2025 | Chief Executive Officer | Sale at price 49.00 per share. | $1.5M |
| Mainolfi Nello | Sep 16, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 2.08 per share. | $62,400 |
Newest 12 of 41 insider transactions in the last two years.
Questions and answers
Who owns the most Kymera Therapeutics stock?
Fidelity Management & Research Co. LLC, with 15.01% of the company (as of September 25, 2026). Next: Baker Bros. Advisors LP (10.52%) and Avoro Capital Advisor LLC (9.09%).
How many institutions own Kymera Therapeutics stock?
294 institutional holdings reports listed Kymera Therapeutics shares in Q2 2026 worth $11.10 billion.
Are Kymera Therapeutics insiders buying or selling the stock?
In the last two years insiders reported 18 sales and 2 purchases (41 transactions in all); the newest on file is from October 29, 2025.
